Lesogaberan Explained

Lesogaberan (AZD-3355) was[1] an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD).[2] As a GABAB receptor agonist,[3] it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD.[4]

Notes and References

  1. Web site: AZD3355. 30 December 2011. AstraZeneca.
  2. Bredenoord, Albert J. . Lesogaberan, a GABAB agonist for the potential treatment of gastroesophageal reflux disease . IDrugs . 2009 . 12 . 9 . 576–584 . 19697277.
  3. Alstermark . 3 . Synthesis and Pharmacological Evaluation of Novel γ-Aminobutyric Acid Type B (GABAB) Receptor Agonists as Gastroesophageal Reflux Inhibitors . Journal of Medicinal Chemistry . 2008 . 51 . 14 . 4315–4320 . 10.1021/jm701425k . 18578471 . Amin . K . Dinn . SR . Elebring . T . Fjellström . O . Fitzpatrick . K . Geiss . WB . Gottfries . J . Guzzo . PR. Harding . James P. . Holmén . Anders . Kothare . Mohit . Lehmann . Anders . Mattsson . Jan P. . Nilsson . Karolina . Sundén . Gunnel . Swanson . Marianne . von Unge . Sverker . Woo . Alex M. . Wyle . Michael J. . Zheng . Xiaozhang .
  4. Brian E. Lacy . Robert Chehade . Michael D. Crowell . Lesogaberan . Drugs of the Future . 2010 . 35 . 12 . 987–992 . 10.1358/dof.2010.035.012.1540661. 258021903 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lesogaberan".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.